Investment Banking
Joint Bookrunner on Retension Pharmaceuticals’ $51.75MM IPO
October 23, 2026
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Retension Pharmaceuticals’ $51.75MM Initial Public Offering
Retension Pharmaceuticals, Inc. (NasdaqCM:RTSN), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 4,312,500 shares of its common stock at an initial public offering price of $12.00 per share, which includes 562,500 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.
The aggregate gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $51.75 million.
Retension intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension (uHTN) and to prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN, with the remainder to be used for general corporate purposes and other operating expenses.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Name:
Stefan Loren, Ph.D.
Title:Managing Director, Life Sciences Investment Banking
Name:
Jonathan Dumont
Title:Director, Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 9195034.1